186 related articles for article (PubMed ID: 23648290)
21. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Gazitt Y; Rothenberg ML; Hilsenbeck SG; Fey V; Thomas C; Montegomrey W
Int J Oncol; 1998 Oct; 13(4):839-48. PubMed ID: 9735415
[TBL] [Abstract][Full Text] [Related]
23. Preclinical combination therapy of clofarabine plus radiation.
Stackhouse MA; Gilbert KS; Scoggins JW; Waud WR
Nucleosides Nucleotides Nucleic Acids; 2012; 31(9):692-705. PubMed ID: 23004932
[TBL] [Abstract][Full Text] [Related]
24. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
[TBL] [Abstract][Full Text] [Related]
25. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
Feng L; Achanta G; Pelicano H; Zhang W; Plunkett W; Huang P
Int J Mol Med; 2000 Jun; 5(6):597-604. PubMed ID: 10812007
[TBL] [Abstract][Full Text] [Related]
26. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
[TBL] [Abstract][Full Text] [Related]
28. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Zoli W; Ricotti L; Tesei A; Ulivi P; Gasperi Campani A; Fabbri F; Gunelli R; Frassineti GL; Amadori D
Clin Cancer Res; 2004 Feb; 10(4):1500-7. PubMed ID: 14977854
[TBL] [Abstract][Full Text] [Related]
29. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
Liu AP; Lee V; Li CK; Ha SY; Chiang AK
Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
[TBL] [Abstract][Full Text] [Related]
30. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.
Achanta G; Pelicano H; Feng L; Plunkett W; Huang P
Cancer Res; 2001 Dec; 61(24):8723-9. PubMed ID: 11751391
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
32. Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation.
Lee YJ; Im JH; Lee DM; Park JS; Won SY; Cho MK; Nam HS; Lee YJ; Lee SH
BMB Rep; 2012 Nov; 45(11):647-52. PubMed ID: 23187004
[TBL] [Abstract][Full Text] [Related]
33. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
34. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
35. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Mitsuno M; Kitajima Y; Ohtaka K; Kai K; Hashiguchi K; Nakamura J; Hiraki M; Noshiro H; Miyazaki K
Int J Oncol; 2010 Feb; 36(2):341-9. PubMed ID: 20043067
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
Karp JE; Ricklis RM; Balakrishnan K; Briel J; Greer J; Gore SD; Smith BD; McDevitt MA; Carraway H; Levis MJ; Gandhi V
Blood; 2007 Sep; 110(6):1762-9. PubMed ID: 17562873
[TBL] [Abstract][Full Text] [Related]
37. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
38. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
39. In vitro assessment of nucleoside analogs in multiple myeloma.
Krett NL; Ayres M; Nabhan C; Ma C; Nowak B; Nawrocki S; Rosen ST; Gandhi V
Cancer Chemother Pharmacol; 2004 Aug; 54(2):113-21. PubMed ID: 15133625
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
